Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Mallinckrodt
Baxter
Medtronic
Moodys

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR UPADACITINIB


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Upadacitinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02049138 ↗ An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Rheumatoid Arthritis Subjects Completed AbbVie Phase 2 2014-01-24 This is a Phase 2, multicenter, open-label extension study in RA subjects. The sub-study is to assess the impact of upadacitinib treatment (15 mg QD and 30 mg QD) with background MTX on immunological responses to Prevnar 13® in RA patients.
NCT02066389 ↗ A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone Completed AbbVie Phase 2 2014-03-26 The primary objective of the study was to compare the safety and efficacy of multiple doses of upadacitinib versus placebo in adults with moderately to severely active rheumatoid arthritis (RA) on stable background methotrexate therapy who had not shown an adequate response to methotrexate alone.
NCT02365649 ↗ A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intoleran Completed AbbVie Phase 2 2015-03-17 To determine the efficacy and safety of multiple doses of ABT-494 in subjects with moderately to severely active Crohn's Disease with a history of inadequate response to or intolerance to Immunomodulators or anti-Tumor Necrosis Factor (TNF) therapy.
NCT02629159 ↗ A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate Active, not recruiting AbbVie Phase 3 2015-12-01 The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to severely active rheumatoid arthritis (RA) who are on a stable background of methotrexate (MTX and who have an inadequate response to MTX.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Upadacitinib

Condition Name

Condition Name for Upadacitinib
Intervention Trials
Rheumatoid Arthritis 14
Atopic Dermatitis 10
Crohn's Disease 4
Rheumatoid Arthritis (RA) 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Upadacitinib
Intervention Trials
Arthritis 20
Arthritis, Rheumatoid 16
Eczema 11
Dermatitis, Atopic 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Upadacitinib

Trials by Country

Trials by Country for Upadacitinib
Location Trials
United States 796
Japan 346
Canada 124
Poland 123
China 106
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Upadacitinib
Location Trials
Texas 33
Florida 33
California 33
Ohio 30
Illinois 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Upadacitinib

Clinical Trial Phase

Clinical Trial Phase for Upadacitinib
Clinical Trial Phase Trials
Phase 4 4
Phase 3 28
Phase 2/Phase 3 1
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Upadacitinib
Clinical Trial Phase Trials
Active, not recruiting 21
Completed 9
Not yet recruiting 7
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Upadacitinib

Sponsor Name

Sponsor Name for Upadacitinib
Sponsor Trials
AbbVie 44
Novartis 1
Lady Davis Institute 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Upadacitinib
Sponsor Trials
Industry 48
Other 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
AstraZeneca
Merck
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.